Nowara M, Fouad YA, Abdel Aziz I, et al. - In this retrospective analysis, researchers documented their single-center experience with exudative Coats’ disease including patient characteristics, presentation, and outcomes of management with the use of adjuvant anti-vascular endothelial growth factor injection (ranibizumab). Records of patients with exudative Coats’ disease (stages 2 and 3) were reviewed retrospectively from April 2016 to November 2020. Extracted data involved clinical and radiological assessment, stage (Shields’ classification), interventions, and follow-up. In the final analysis, 16 eyes were included, of which 4 (25%) were stage 2 and 12 (75%) were stage 3. In conjunction with ablation therapy, all eyes underwent intravitreal ranibizumab injection, 14 (87.5%) underwent cryotherapy, 4 (25%) underwent laser ablation, 3 (18.75%) underwent external subretinal fluid drainage, and 3 (18.75%) underwent buckle or vitrectomy surgery. The combination of intravitreal injection of ranibizumab with ablation therapy is effective in managing exudative Coats’ disease. External drainage should be maintained if ablation therapy is not feasible.